Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Production and characterization of virus-free, CRISPR-CAR T cells capable of inducing solid tumor regression
Katherine P. Mueller, Nicole J. Piscopo, Matthew H. Forsberg, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 9, pp. e004446-e004446
Open Access | Times Cited: 40

Showing 1-25 of 40 citing articles:

The Past, Present, and Future of Non-Viral CAR T Cells
Alex Moretti, Marianna Ponzo, Charles A. Nicolette, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 96
CRISPR–Cas9 applications in T cells and adoptive T cell therapies
Xiaoying Chen, Shuhan Zhong, Yonghao Zhan, et al.
Cellular & Molecular Biology Letters (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 19
Advanced Delivery Systems for Gene Editing: A Comprehensive Review from the GenE-HumDi COST Action Working group
Alessia Cavazza, Francisco J Molina-Estévez, Álvaro Plaza Reyes, et al.
Molecular Therapy — Nucleic Acids (2025) Vol. 36, Iss. 1, pp. 102457-102457
Open Access | Times Cited: 3
Non-viral chimeric antigen receptor (CAR) T cells going viral
Hyatt Balke‐Want, Vimal Keerthi, Amaia Cadiñanos-Garai, et al.
Immuno-Oncology Technology (2023) Vol. 18, pp. 100375-100375
Open Access | Times Cited: 39
GD2-targeting therapy: a comparative analysis of approaches and promising directions
Julia Philippova, Julia Shevchenko, С. В. Сенников
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 14
Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies
Shengkang Huang, Xinyu Wang, Yu Wang, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 22
Homology-independent targeted insertion (HITI) enables guided CAR knock-in and efficient clinical scale CAR-T cell manufacturing
Hyatt Balke‐Want, Vimal Keerthi, Nikolaos Gkitsas, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 20
Increasing Gene Editing Efficiency via CRISPR/Cas9- or Cas12a-Mediated Knock-In in Primary Human T Cells
Natalia Kruglova, М. В. Шепелев
Biomedicines (2024) Vol. 12, Iss. 1, pp. 119-119
Open Access | Times Cited: 6
Metabolic priming of GD2 TRAC-CAR T cells during manufacturing promotes memory phenotypes while enhancing persistence
Dan Cappabianca, Dan L. Pham, Matthew H. Forsberg, et al.
Molecular Therapy — Methods & Clinical Development (2024) Vol. 32, Iss. 2, pp. 101249-101249
Open Access | Times Cited: 6
CRISPR-Cas and CRISPR-based screening system for precise gene editing and targeted cancer therapy
Mingming Qin, Chunhao Deng, Liewei Wen, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 5
Metabolic priming of GD2TRAC-CAR T cells during manufacturing promotes memory phenotypes while enhancing persistence
Dan Cappabianca, Dan L. Pham, Matthew H. Forsberg, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 4
Label free metabolic imaging to enhance the efficacy of Chimeric Antigen Receptor T cell therapy
Dan L. Pham, Daniel Cappabianca, Matthew H. Forsberg, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 4
Effectiveness and safety of anti-BCMA chimeric antigen receptor T-cell treatment in relapsed/refractory multiple myeloma: a comprehensive review and meta-analysis of prospective clinical trials
Dingyuan Hu, Liming Chen, Diqin Yan, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 10
Non-viral vectors for chimeric antigen receptor immunotherapy
Sandy Tretbar, Joel G. Rurik, Even H Rustad, et al.
Nature Reviews Methods Primers (2024) Vol. 4, Iss. 1
Closed Access | Times Cited: 4
Efficient Nonviral Integration of Large Transgenes into Human T Cells Using Cas9-CLIPT
Anna Tommasi, Dan Cappabianca, Madison Bugel, et al.
Molecular Therapy — Methods & Clinical Development (2025) Vol. 33, Iss. 1, pp. 101437-101437
Open Access
CAR‐T Cell Manufacturing for Hematological and Solid Tumors: From the Preclinical to Clinical Point of View
Sara Capolla, Maria Rasool, Giuseppe Toffoli, et al.
Cancer Medicine (2025) Vol. 14, Iss. 5
Open Access
PRGN-2009 and bintrafusp alfa for patients with advanced or metastatic human papillomavirus-associated cancer
Charalampos S. Floudas, Meghali Goswami, Renee N. Donahue, et al.
Cancer Immunology Immunotherapy (2025) Vol. 74, Iss. 5
Open Access
Systematic high-throughput evaluation reveals FrCas9’s superior specificity and efficiency for therapeutic genome editing
Rui Tian, Xun Tian, Yang Meiying, et al.
Science Advances (2025) Vol. 11, Iss. 13
Closed Access
New insights on potency assays from recent advances and discoveries in CAR T-cell therapy
Lipei Shao, Yanyan Zheng, Robert Somerville, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Comparative Study of the Effect of Radiation Delivered by Lutetium-177 or Actinium-225 on Anti-GD2 Chimeric Antigen Receptor T Cell Viability and Functions
Quaovi H. Sodji, Matthew H. Forsberg, Dan Cappabianca, et al.
Cancers (2023) Vol. 16, Iss. 1, pp. 191-191
Open Access | Times Cited: 9
Harnessing the Transcriptional Signatures of CAR-T-Cells and Leukemia/Lymphoma Using Single-Cell Sequencing Technologies
Yu‐Mei Liao, Shih‐Hsien Hsu, Shyh‐Shin Chiou
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 4, pp. 2416-2416
Open Access | Times Cited: 3
GMP-manufactured CRISPR/Cas9 technology as an advantageous tool to support cancer immunotherapy
Matteo Caforio, Stefano Iacovelli, Concetta Quintarelli, et al.
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 3
Engineering T Cell Development for the Next Generation of Stem Cell-Derived Immunotherapies
Yale S. Michaels, Lauren J. Durland, Peter W. Zandstra
GEN Biotechnology (2023) Vol. 2, Iss. 2, pp. 106-119
Open Access | Times Cited: 7
Advances in manufacturing chimeric antigen receptor immune cell therapies
Apoorva Ramamurthy, Anna Tommasi, Krishanu Saha
Seminars in Immunopathology (2024) Vol. 46, Iss. 5
Closed Access | Times Cited: 2
Label-free in vitro assays predict the potency of anti-disialoganglioside chimeric antigen receptor T-cell products
Meghan Logun, Maxwell B. Colonna, Katherine P. Mueller, et al.
Cytotherapy (2023) Vol. 25, Iss. 6, pp. 670-682
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top